![conference banner](/images/conference-banner.jpeg)
Abstract
Alterations in gait and balance are manifest in numerous neurological disorders such as the ataxias and Parkinson's disease, and may occur as a consequence of stroke, traumatic brain injury and chemical insults to the brain. Although the underlying etiology of these disorders differs, disturbances in gait and balance appear to reflect deficits in cholinergic pathways within the brain. During the past 40 years, both clinical case studies and preclinical data have provided evidence that nicotinic cholinergic activation is beneficial for alleviating gait and balance deficits in many disorders. Further, studies indicate that activation of neuronal nicotinic receptors leads to neuroprotective and neurotrophic actions. And yet, despite these findings, there hsas been no concerted effort to develop neuronal nicotinic agonists for the treatment of abnormal gait and balance. The goal of this review is to shed light on the therapeutic benefit of the cholinergic nicotinic system for the treatment of ataxia, and discuss the challenges and limitations associated with developing drugs to treat disorders involving deficits in gait and balance.
Keywords: Ataxias, neuronal nicotinic receptor, varenicline, nicotine, gait, balance.
Current Pharmaceutical Design
Title:Regulation of Gait and Balance: The Underappreciated Role of Neuronal Nicotinic Receptor Agonists
Volume: 22 Issue: 14
Author(s): Michael F. Young and Lynn Wecker
Affiliation:
Keywords: Ataxias, neuronal nicotinic receptor, varenicline, nicotine, gait, balance.
Abstract: Alterations in gait and balance are manifest in numerous neurological disorders such as the ataxias and Parkinson's disease, and may occur as a consequence of stroke, traumatic brain injury and chemical insults to the brain. Although the underlying etiology of these disorders differs, disturbances in gait and balance appear to reflect deficits in cholinergic pathways within the brain. During the past 40 years, both clinical case studies and preclinical data have provided evidence that nicotinic cholinergic activation is beneficial for alleviating gait and balance deficits in many disorders. Further, studies indicate that activation of neuronal nicotinic receptors leads to neuroprotective and neurotrophic actions. And yet, despite these findings, there hsas been no concerted effort to develop neuronal nicotinic agonists for the treatment of abnormal gait and balance. The goal of this review is to shed light on the therapeutic benefit of the cholinergic nicotinic system for the treatment of ataxia, and discuss the challenges and limitations associated with developing drugs to treat disorders involving deficits in gait and balance.
Export Options
About this article
Cite this article as:
Young F. Michael and Wecker Lynn, Regulation of Gait and Balance: The Underappreciated Role of Neuronal Nicotinic Receptor Agonists, Current Pharmaceutical Design 2016; 22 (14) . https://dx.doi.org/10.2174/1381612822666160127111848
DOI https://dx.doi.org/10.2174/1381612822666160127111848 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design of Bioartificial Pancreas with Functional Micro/Nano-Based Encapsulation of Islets
Current Pharmaceutical Biotechnology Challenges of Delirium Management in Patients with Traumatic Brain Injury: From Pathophysiology to Clinical Practice
Current Neuropharmacology Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry Partners in Crime: NGF and BDNF in Visceral Dysfunction
Current Neuropharmacology The Controversial Role of Adenosine A2A Receptor Antagonists as Neuro-protective Agents
Current Medicinal Chemistry - Central Nervous System Agents What can Adenosine Neuromodulation do for Neuroprotection?
Current Drug Targets - CNS & Neurological Disorders From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?
Current Pharmaceutical Design Consequences of the α-Ketoglutarate Dehydrogenase Inhibition for Neuronal Metabolism and Survival: Implications for Neurodegenerative Diseases
Current Medicinal Chemistry <i>Punica granatum</i> as a Source of Natural Antioxidant and Antimicrobial Agent: A Comprehensive Review on Related Investigations
Current Drug Discovery Technologies Topical Delivery of Antioxidants
Current Drug Delivery COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry The Multifunctional Protein C System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Insulin and the Brain
Current Diabetes Reviews Artificial Intelligence in The Management of Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Early Hematoma Enlargement in Primary Intracerebral Hemorrhage
Current Drug Targets Advances in Pharmacological Activities and Mechanisms of Glycyrrhizic Acid
Current Medicinal Chemistry Angelica Injection Improves Functional Recovery and Motoneuron Maintenance with Increased Expression of Brain Derived Neurotrophic Factor and Nerve Growth Factor
Current Neurovascular Research Expression and Function of MicroRNAs in Heart Disease
Current Drug Targets Diabetes Mellitus and Energy Dysmetabolism in Alzheimer’s Disease: Understanding the Relationships and Potential Therapeutic Targets
Current Diabetes Reviews